In the high-stakes world of biopharmaceuticals, every now and then, a clinical-stage upstart captures the imagination of the analyst community. While the sector is littered with companies that fail to commercialize their science, a select few manage to deliver life-changing windfalls for early investors. Right now, Wall Street is signaling that Viking Therapeutics (VKTX) could be one of those rare exceptions.
The numbers tell a compelling story. The stock’s current consensus price target stands at $92.94, implying a potential upside of more than 200% from current levels. But one analyst sees even greater heights. Justin Zelin of BTIG has slapped a $125 price target on the stock, suggesting a jaw-dropping surge of over 300%.
The question on every investor’s mind is simple: What does this unprofitable pharmaceutical startup have that has the pros so convinced?
The answer lies in a single compound: VK2735. This is Viking’s lead drug candidate, a weight-loss therapy currently in Phase 3 trials. While the company does have other irons in the fire, investor enthusiasm is overwhelmingly pinned on this prospect.
VK2735 is a glucagon-like peptide 1 (GLP-1) receptor agonist, placing it in the same hotly contested arena as Eli Lilly’s Orforglipron and Novo Nordisk’s Wegovy. From a scientific standpoint, this is familiar territory for regulators; the mechanism of action is well-understood, which could smooth the path toward FDA review once the trials are complete.
However, Viking’s candidate may possess a distinct competitive edge: tolerability. While early data suggests VK2735 might not be significantly more potent than existing blockbusters, patients appear to stick with it longer. In the world of chronic weight management, adherence is a critical metric. If patients are less likely to discontinue treatment due to side effects, that alone could be a game-changer.
Furthermore, Viking is thinking ahead about patient convenience. While the current Phase 3 trial focuses on subcutaneous injections, the company also has an oral version of VK2735 advancing through Phase 2 trials. This dual-route strategy could offer significant flexibility in how the drug is marketed and administered.
Zelin has also floated another intriguing possibility: Viking could become a prime acquisition target. For Big Pharma giants looking to buy their way into the lucrative weight-loss market with a well-developed candidate, Viking represents a very attractive opportunity.
Of course, the skeptics have valid points. The most obvious headwind is competition. Novo Nordisk and Eli Lilly already dominate the GLP-1 landscape with products that are very similar to VK2735. In a crowded field, will a marginal difference in tolerability be enough to sway prescribers and patients?
Perhaps it doesn’t need to be. Viking doesn’t have to beat the giants to win big for shareholders; it just needs to capture a respectable slice of a rapidly expanding market. According to Precedence Research, the global GLP-1 weight loss drug market is projected to explode from $8.2 billion last year to over $66 billion by 2035.
To put that in perspective, Viking Therapeutics currently has a market capitalization of less than $4 billion. Even capturing a tiny fraction of that future revenue stream could easily justify a significantly higher stock price. In that context, BTIG’s $125 target starts to look less like hype and more like math.
While all eyes are on VK2735, Viking is quietly building a pipeline to support long-term growth. The company is gearing up to file an investigational new drug application for a new candidate: a dual amylin and calcitonin receptor agonist.
These receptors play key roles in metabolism, making them attractive targets for next-generation obesity treatments. Viking envisions this drug potentially serving as a standalone therapy for patients who aren’t candidates for GLP-1s, or as a combination therapy to enhance efficacy.
This pipeline expansion is a crucial signal. It demonstrates that Viking is not a one-trick pony; it is actively innovating to create a sustainable franchise in metabolic disorders. With data readouts, late-stage trial progress, and new trial initiations all on the docket, this year could be pivotal for the company.
So, is now the time to buy Viking stock? As with all clinical-stage biotechs, the answer depends entirely on your risk tolerance.
Viking has no products on the market, and its fortunes hinge entirely on the success of VK2735. While the data so far is promising, the inherent risks of drug development remain. The finish line—FDA approval—is still a long way off. For conservative investors, waiting for clearer signals might be the prudent move.
But for those willing to embrace volatility in exchange for asymmetric upside, Viking presents a compelling narrative. The weight-loss drug market is one of the fastest-growing sectors in healthcare, and Viking has a credible candidate with a potential edge. If clinical development proceeds as hoped, this year’s milestones could be just the prologue to a much longer growth story.
